Optimisation of a potent series of HCV helicase drug candidates

Styliani Loukatou, Louis Papageorgiou, Dimitrios Vlachakis


Bailey TR, Diana GD & Nitz TJ 1997 Piperidine derivatives, pharmaceutical compositions thereof and their use in the treatment of hepatitis c. WO 1997036554 A1

Balatsos N, Vlachakis D, Chatzigeorgiou V, Manta S, Komiotis D, Vlassi M & Stathopoulos C 2012 Kinetic and in silico analysis of the slow-binding inhibition of human poly(A)-specific ribonuclease (PARN) by novel nucleoside analogues. Biochimie 94 214-221

Brass V, Moradpour D & Blum HE 2006 Molecular virology of Hepatitis C Virus (HCV): 2006 Update. Int J Med Sci 3 29-34

Craxì A, Laffi G & Zignego AL 2008 Hepatitis C virus (HCV) infection: A systemic disease. Mol Asp Med 29 85-95

Dalkas GA, Vlachakis D, Tsagkrasoulis D, Kastania A & Kossida S 2012. State-of-the-art technology in modern computer-aided drug design. Brief Bioinform 14 745-752

Hayashi N & Takehara T 2006 Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 41 17-27

Janetka JW, Ledford BE & Mullican MD 2000 Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase. World patent WO 2000024725 A1

Kandil S, Biondaro S, Vlachakis D, Cummins AC, Coluccia A, Berry C, Leyssen P, Neyts J & Brancale A 2009 Discovery of a novel HCV helicase inhibitor by a de novo drug design approach. Bioorg Med Chem Lett 19 2935-2937

Kim JL, Morgenstern KA, Griffith JP, Dwyer MD, Thomson JA, Murcko MA, Lin C & Caron PR 1998 Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 6 89-100

Lam AM & Frick DN 2006 Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J Virol 80 404-411

Lam AMI, Keeney D & Frick DN 2003 Two novel conserved motifs in the Hepatitis C Virus NS3 protein critical for helicase action. J Biol Chem 278 44514-44524

Louis P, Dimitrios V, Vassiliki Lila K, Nikitas P & Sophia K 2013 Computer-aided drug design and biological evaluation of novel Anti-Greek Goat Encephalitis agents. Int J Sys Biol Biomed Tech 2 1-16

Loukatou S, Papageorgiou L, Fakourelis P, Filtisi A, Polychronidou E, Bassis I, Megalooikonomou V, Makalowski W, Vlachakis D & Kossida S 2014 Molecular dynamics simulations through GPU video games technologies. J Mol Biochem 3 64-71

Maga G, Gemma S, Fattorusso C, Locatelli GA, Butini S, Persico M, Kukreja G, Romano MP, Chiasserini L & Savini L 2005 Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663. Biochemistry 44 9637-9644

Nikitas P, Dimitrios V, Arianna F, Paraskevas F, Louis P, Vasileios M & Sophia K. 2013 State-of-the-art GPGPU applications in bioinformatics. Int J Sys Biol Biomed Tech 2 24-48

Sellis D, Vlachakis D & Vlassi M 2009 Gromita: A fully integrated graphical user interface to Gromacs 4. Bioinform Biol Ins 3 99-102

Soriano V, Peters MG & Zeuzem S 2009 New therapies for Hepatitis C Virus infection. Clin Infectious Dis 48 313-320

Vlachakis D, Argiro A & Kossida S 2013a An update on virology and emerging viral epidemics. J Mol Biochem 2 80-84

Vlachakis D, Bencurova E, Papangelopoulos N & Kossida S 2014 Current state-of-the-art molecular dynamics methods and applications. Adv Protein Chem Struct Biol 94 269-313

Vlachakis D, Champeris Tsaniras S, Feidakis C & Kossida S 2013b Molecular modelling study of the 3D structure of the biglycan core protein, using homology modelling techniques. J Mol Biochem 2 85-93

Vlachakis D, Karozou A & Kossida S 2013c 3D Molecular modelling study of the H7N9 RNA-dependent RNA polymerase as an emerging pharmacological target. Influenza Res Treat 2013 645348

Vlachakis D, Kontopoulos DG & Kossida S 2013d Space constrained homology modelling: the paradigm of the RNA-dependent RNA polymerase of dengue (type II) virus. Comput Math Methods Med 2013 108910

Vlachakis D & Kossida S 2013 Molecular modeling and pharmacophore elucidation study of the Classical Swine Fever virus helicase as a promising pharmacological target. PeerJ 1 e85

Vlachakis D, Koumandou VL & Kossida S 2013e A holistic evolutionary and structural study of flaviviridae provides insights into the function and inhibition of HCV helicase. PeerJ 1 e74

Vlachakis D, Pavlopoulou A, Tsiliki G, Komiotis D, Stathopoulos C, Balatsos NA & Kossida S 2012 An integrated in silico approach to design specific inhibitors targeting human poly(a)-specific ribonuclease. PloS one 7 e51113

Vlachakis D, Tsiliki G & Kossida S 2013f 3D Molecular modelling of the helicase enzyme of the Endemic, Zoonotic Greek Goat Encephalitis Virus. Comm Comp Inf Sci 383 165-171

Zhang N, Chen HM, Koch V, Schmitz H, Liao CL, Bretner M, Bhadti VS, Fattom AI, Naso RB & Hosmane RS 2003 Ring-expanded ("fat") nucleoside and nucleotide analogues exhibit potent in vitro activity against flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus. J Med Chem 46 4149-4164

Full Text: PDF


  • There are currently no refbacks.

Copyright © 2017 Lorem Ipsum Press